Altered Biodistribution of Radiopharmaceuticals: Role of Radiochemical/Pharmaceutical Purity, Physiological, and Pharmacologic Factors

Seminars in Nuclear Medicine

Volumn 40, Issue 4, 2010, Pages 220-241

  Vallabhajosula, Shankar ^a   Killeen, Ronan P ^a   Osborne, Joseph R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; ARCITUMOMAB TC 99M; BUTILFENIN; CAPROMAB PENDETIDE IN 111; CEASCAN; CISPLATIN; COLLOID TC 99M; CYSTEINE ETHYL ESTER TC 99M; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM CITRATE GA 67; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IBRITUMOMAB TIUXETAN; INDIUM 111; INSULIN; IODINE 123; IODINE 131; MACROSALB TC 99M; MEBROFENIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MORPHINE; OCTREOTIDE; PENTETATE INDIUM; PENTETREOTIDE; PENTETREOTIDE IN 111; PERTECHNETIC ACID TC 99M; PROSTACINT; RACLOPRIDE C 11; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; TETROFOSMIN TC 99M; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTIFACT; BLOOD CLOT; BONE SCINTISCANNING; DOSIMETRY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG IMPURITY; DRUG MIXTURE; DRUG SYNTHESIS; GLUCOSE METABOLISM; HEATING; HOMEOSTASIS; HUMAN; IONIC STRENGTH; ISOTOPE LABELING; MEDICATION ERROR; MYOCARDIAL PERFUSION IMAGING; NEUROENDOCRINE TUMOR; NUCLEAR MEDICINE; OXIDATION REDUCTION REACTION; PARTICLE SIZE; PATIENT CARE; PATIENT POSITIONING; PH; PLASMA PROTEIN BINDING; POSITRON EMISSION TOMOGRAPHY; PROTEIN LOCALIZATION; QUALITY CONTROL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION SAFETY; RADIOCHEMISTRY; RADIOLYSIS; REVIEW; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC USE; PROCEDURES; TISSUE DISTRIBUTION;

ARTIFACTS; HUMANS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 77952704302     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2010.02.004     Document Type: Review

References (81)

1. Hladik W.B., and Norenberg J.P. Problems associated with the clinical use of radiopharma-ceuticals: A proposed classification system and trouble shooting guide. Eur J Nucl Med 23 (1996) 997-1002
2. Lentle B.C., Scott J.R., Noujaim A.A., et al. latrogenic alterations in radionuclide biodistributions. Semin Nucl Med 9 (1979) 131-143
3. Hung J.C., Pronto J.A., and Hammers R.J. Radiopharmaceutical-related pitfalls and artifacts. Semi. Nucl Med 26 (1996) 208-255
4. Hojelse C., Kristensen K., and Sampson C.B. Factors which affect the integrity of radiopharmaceuticals. In: Sampson C.B. (Ed). Textbook of Radiopharmacy, Theory and Practice (ed 2) (1994), Gordon and Breach Science Publishers, Amsterdam 145-152
5. Hladik W.B., Nigg N.K., and Rhodes B.A. Drug induced changes in the biologic distribution of radiopharmaceuticals. Semin Nucl Med 12 (1982) 184-218
6. Hesselewood S., and Leung E. Drug interactions with radiopharmaceuticals. Eur J Nucl Med 21 (1994) 348-356
7. Sampson C.B. Adverse reactions and drug interactions with radiopharmaceuticals. Drug Saf 8 (1993) 280-294
8. Leung E., and Hesslewood S. Use of non-radioactive drugs in nuclear medicine. Pharm J 249 (1992) HS32-HS36
9. Saha G.B. Adverse reactions to and altered biodistribution of radiopharmaceuticals. In: Saha G.B. (Ed). Fundamentals of Nuclear Pharmacy (ed 4) (2004), Springer, New York 351-353
10. Chamarthy M., and Travin M.I. Altered biodistribution and incidental findings on myocardial perfusion imaging. Semin Nucl Med 40 (2010) 257-270
11. Zuckier L.S., and Freeman L.M. Nonosseous, nonurologic uptake on bone scintigraphy: atlas and analysis. Semin Nucl Med 40 (2010) 242-256
12. Cohade C. Altered biodistribution on FDG-PET with emphasis on brown fat and insulin effect. Semin Nucl Med 40 (2010) 283-293
13. Liu Y., Ghesani N.V., and Zuckier L.S. Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy. Semin Nucl Med 40 (2010) 294-315
14. Shapiro B., Rufini V., Janwan A., et al. Artifacts, anatomic and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I Scans in patients with thyroid cancer. Semin Nucl Med 30 (2000) 115-315
15. Love C., and Palestro C.J. Altered biodistribution and incidental findings on gallium and labeled leukocyte/bone marrow scans. Semin Nucl Med 40 (2010) 271-282
16. Vallabhajosula S. Molecular Imaging: Radiopharmaceuticals for PET and SPECT (ed 1) (2009), Springer, Berlin
17. Deutsch E., Libson K., Jurisson S., et al. Technetium chemistry and technetium radiopharmaceuticals. Prog Inorg Chem 30 (1983) 75-139
18. Nosco D.L., Wolfangel R.G., Bushman M.J., et al. Technetium-99m MAG3: Labeling conditions and quality control. J Nucl Med Technol 121 (1993) 69-74
19. Morrissey G.J., and Powe J.E. Microwave preparation of technetium-99m sulfur colloid. J Nucl Med Technol 20 (1992) 159-162
20. Henkin R.E., Woodruff A., Chang W., et al. The effect of radiopharmaceutical incubation time on bone scan quality. Radiology 135 (1980) 463-466
21. Russell C.D., Rowell K., and Scott J.W. Quality control of technetium-99m DTPA: Correlation of analytic tests with in vivo protein binding in man. J Nucl Med 27 (1986) 560-562
22. McBride M.H.D., Shaw S.M., and Kessler W.V. Deterioration of stannous 1on in radiopharmaceutical kits during storage. Am J Hosp Pharm 36 (1979) 1370-1372
23. Owunwanne A., Church L.B., and Blau M. Effect of oxygen on the reduction of pertechnetate by stannous ion. J Nucl Med 18 (1977) 822-826
24. Bavne V.J., Forster A.M., and Tyrrell D.A. Use of sodium iodide to overcome the eluate age restriction for Ceretec® reconstitution. Nucl Med Commun 10 (1989) 29-33
25. Kobayashi H., Suzuki K.H., Sakahara H., et al. Oxygen bubbling can improve the labeling of pentavalent technetium-99m dimercaptosuccinic acid. Eur J Nucl Med 22 (1995) 559-562
26. Green J.M., Donohoe M.E., Foster M.E., et al. Thin layer chromatographic procedures for the characterization of technetium-99m bicisate. J Nucl Med Technol 22 (1994) 21-26
27. 99mTc sulfur colloid preparations with different buffers. J Nucl Med Technol 12 (1984) 16-18
28. 99mTc-MDP biodistribution. J Radioanal Nucl Chem Artic 122 (1988) 57-63
29. Wener R.E., and Thakur M.L. Chemistry of gallium and indium radiopharmaceuticals. In: Welch M.J., and Redvanly C.S. (Eds). Handbook of Radiopharmaceuticals (2003), John Wiley & Sons, West Sussex, England
30. Vallabhajosula S., Harwig J.F., Siemsen J.K., et al. Radiogallium localization in tumors: Blood binding and transport and the role of transferrin. J Nucl Med 21 (1980) 650-656
31. Hoffer P. Gallium: Mechanisms. J Nucl Med 21 (1980) 282-285
32. 67Ga localization in malignant disease. Nucl Med Biol 23 (1996) 745-751
33. 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 33 (2003) 917-920
34. Steffel F.G., and Rao S. Rapid and simple methods for labeling white blood cells and platelets with indium-111 oxine. J Nucl Med Technol 15 (1987) 61-65
35. McAfee J.G., Gagne G.M., Subramanian G., et al. Distribution of leukocytes labeled with In-llloxine in dogs with acute inflammatory lesions. J Nucl Med 21 (1980) 1059-1068
36. Hunter V.W., Kulkarni M.V., and Price R. Thallous vs thallic TI-201: Factors influencing biodistribution and myocardial turnover. J Nucl Med 22 (1981) 82 (abstr)
37. - symporter (NIS): Imaging and therapeutic applications. Semin Nucl Med 34 (2004) 23-31
38. Sternthal E., Lipworth L., Stanley B., et al. Suppression of thyroid radioiodine uptake by various doses of stable iodine. N Engl J Med 303 (1980) 1083-1088
39. Oswald W.M., Hung J.C., and Gross G.P. A study to measure the volatility of liquid 1-131 for clinical applications. J Nucl Med Technol 122 (1994) 123
40. Yu M.-D., Huang W.-S., Cherng C.-C., et al. The effect of formulation on reduced radioiodide thyroid uptake. J Nucl Med 43 (2002) 56-60
41. 131I. Thyroidology 9 (1999) 347-352
42. 131I-labeled metaiodobenzylguanidine for therapeutic use. Nucl Med Commun 14 (1993) 819-822
43. 18F-labeled positron emission tomographic radiopharmaceuticals in oncology: An overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 37 (2007) 400-419
44. Ongseng F., Goldfarb C.R., and Finestone H. Axillary lymph node uptake of technetium-99m-MDP. J Nucl Med 36 (1995) 1797-1799
45. Hoop B. The infiltrated radiopharmaceutical injection: Risk considerations. J Nucl Med 32 (1991) 890-891
46. Piers D.A., and Beekhuis H. Local radiation dose from extravascular T1-201. J Nucl Med 28 (1987) 684 (abstr)
47. Goldberg E., and Lieberman C. "Hot spots" in lung scans. J Nucl Med 18 (1977) 499
48. Gentili A., Miron S.D., and Adler L.P. Review of some common artifacts in nuclear medicine. Clin Nucl Med 19 (1994) 138-143
49. 99mTc by iodinated antiseptics (1977), J Nucl Med 18:1139-1140 (letter)
50. Peterson E.M., Ryan J.W., and Martin W.B. Gastric activity on Tc-99m oxidronate bone scans can be caused by isopropyl alcohol. J Nucl Med 27 (1986) 1090 (abstr)
51. Gnanasegaran G., Cook G., Adamson K., et al. Patterns, variants, artifacts, and pitfalls in conventional radionuclide bone imaging and SPECT/CT. Semin Nucl Med 39 (2009) 380-395
52. 99mTc-methylene diphosphonate uptake of bone scans and a review of the literature. Nucl Med Commun 27 (2006) 877-885
53. Loutfi I., Collier B.D., and Mohammed A.M. Nonosseous abnormalities on bone scans. J Nucl Med Technol 31 (2003) 149-153
54. Griffeth L.K. Use of PET/CT scanning in cancer patients: Technical and practical considerations. Proc (Bayl Univ Med Cent) 18 (2005) 321-330
55. Cook G.J.R., Fogelman I., and Maisey M.N. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation. Semin Nucl Med 26 (1996) 308-314
56. Tu D.-G., Yao W.-J., Chang T.-W., et al. Flare phenomenon in positron emission tomography in a case of breast cancer-a pitfall of positron emission tomography imaging interpretation. Clin Imaging 33 (2009) 468-470
57. 18F-FDG imaging: Pitfalls and artifacts. J Nucl Med Technol 33 (2005) 145-155
58. Kostakoglu L., Hardoff R., Mirtcheva R., et al. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics 24 (2004) 1411-1431
59. Lindholm P., Minn H., and Leskinen-Kallio S. Influence of the blood glucose concentration on FDG uptake in cancer: A PET study. J Nucl Med 34 (1993) 1-6
60. 18F-FDG PET in diabetic cancer patients. J Nucl Med 50 (2009) 178-183
61. Liu Y. Benign ovarian and endometrial uptake on FDG-PET/CT. Ann Nucl Med 23 (2009) 107-112
62. Schelbert H.R. Positron emission tomography of the heart: Methodology, findings in the normal and disease heart, and clinical applications. In: Phelps M.E. (Ed). PET: Molecular Imaging and Its Clinical Applications (2004), Springer, New York
63. Kailasnath P, Sinusas AJ: Comparison of Tl-201, with Tc-99m labeled myocardial perfusion agents: Technical physiologic and clinical issues. J Nucl Cardiol 8:482-498
64. 99mTc-tetroformin. Ann Nucl Med 18 (2004) 79-95
65. Morris L.F., Waman A.D., and Braunstein G.D. Thyroid stunning. Thyroidology 13 (2003) 333-340
66. 131I scans in patients with thyroid cancer. Semin Nucl Med 30 (2000) 115-132
67. Smith J.R., and Oates E. Radionuclide imaging of the thyroid gland: Patterns, pearls and pitfalls. Clin Nucl Med 29 (2004) 181-193
68. Goldsmith S.J., and Vallabhajosula S. Clinically proven radiopharmaceuticals for infection imaging: Mechanisms and applications. Semin Nucl Med 39 (2009) 2-10
69. Rufini V., Calcagni M.L., and Baum R.P. Imaging of neuroendocrine tumors. Semin Nucl Med 36 (2006) 228-247
70. Agostini D., Verberne H.J., Hamon A., et al. Cardiac 123I-mIBG scintigraphy in heart failure. Q J Nucl Med Mol Imaging 52 (2008) 369-377
71. Nakajima K., Yoshita M., Matsuo S., et al. Iodine-123 mIBG sympathetic imaging in Lewy body diseases and related movement disorders. Q J Nucl Med Mol Imaging 52 (2008) 378-387
72. 1231-mIBG uptake in Parkinson's disease. Acta Neurol Scand 97 (1998) 303-306
73. Taneja S.S. ProstaScint scan: Contemporary use in clinical practice. Rev Urol 6 suppl 10 (2004) S19-S28
74. 90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. J Nucl Med Technol 31 (2003) 61-68
75. Goldsmith S.J. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med 40 (2010) 122-135
76. Conti P.S., White C., Pieslor P., et al. The role of imaging with 111In-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: Results from a Zevalin Imaging Registry. J Nucl Med 46 (2005) 1812-1818
77. Sampson C.B., and Cox P.H. Effect of patient medication and other factors on the biodistribution of radiopharmaceuticals. In: Sampson C.B. (Ed). Texbook of Radiopharmacy, Theory and Practice (ed 2) (1994), Gordon and Breach Science Publishers, Amsterdam 215-227
78. Morrison R.T., and Steuart R.D. Delayed massive soft tissue uptake of Tc-99m MDP after radiation therapy for cancer of the breast. Clin Nucl Med 20 (1995) 770-771
79. Mankoff D.A., Dunnwald L.K., Gralow J.R., et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 44 (2003) 1806-1814
80. Dehadashi F., Flanagan F.L., Mortimer J.E., et al. Positron emission tomography assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 26 (1999) 51-56
81. Zaplatnikov K., Menzel C., Dobert N., et al. Drug interference with mIBG uptake in a patient with metastatic paraganglioma. Br J Radiol 77 (2004) 525-527